FDA Hits Guardian Drug for Lack of Quality Controls, Secure Data Post author:Sam Post published:April 11, 2017 Post category:Drug Industry Daily The FDA cited Guardian Drug Company over quality and data storage issues. Source: Drug Industry Daily You Might Also Like Novartis Considers Appealing $1.5 Million Whistleblower Verdict February 27, 2019 Fasenra Misses in Phase 3 For Eosinophilic Esophagitis October 25, 2022 Eli Lilly and ImmunoGen Seal Antibody-Drug Candidate Deal With $1.7 Billion Potential February 15, 2022
Eli Lilly and ImmunoGen Seal Antibody-Drug Candidate Deal With $1.7 Billion Potential February 15, 2022